Optimal serum phenylalanine for adult patients with phenylketonuria

Molecular Genetics and Metabolism

Volumn 110, Issue 4, 2013, Pages 424-430

  Okano, Yoshiyuki ^a   Nagasaka, Hironori ^b  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b TAKARAZUKA CITY HOSPITAL   (Japan)

Author keywords

Magnetic resonance imaging; Nitric oxide; Oxidative stress; Oxysterol; Phenylalanine; Phenylketonuria

Indexed keywords

CHOLESTEROL; COLECALCIFEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; OXYSTEROL; PHENYLALANINE; VITAMIN D;

ADULT; AMINO ACID BLOOD LEVEL; BONE METABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DIET THERAPY; HUMAN; HYPERPHENYLALANINEMIA; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOLYSIS; OXIDATIVE STRESS; PHENYLKETONURIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOMETRY; REVIEW; WHITE MATTER;

ADCS; ADMA; APPARENT DIFFUSION COEFFICIENTS; ASYMMETRIC DIMETHYLARGININE; GLUTATHIONE PEROXIDASE; GPX; HYDROXYCHOLESTEROL; LDL; LOW-DENSITY LIPOPROTEIN; MAGNETIC RESONANCE IMAGING; MALONDIALDEHYDE-MODIFIED LOW-DENSITY LIPOPROTEIN; MDA-LDL; MRI; NITRATE/NITRITE AS STABLE METABOLITES OF NITRIC OXIDE; NITRIC OXIDE; NO; NOX; OH CHOLESTEROL; OXIDATIVE STRESS; OXYSTEROL; PHENYLALANINE; PHENYLKETONURIA; PKU; SOD; SUPEROXIDE-DISMUTASE; TAR; TBARS; THIOBARBITURIC ACID-REACTIVE SPECIES; TOTAL ANTIOXIDANT REACTIVITY;

ADULT; BRAIN; CHOLESTEROL; HUMANS; MAGNETIC RESONANCE IMAGING; NITRIC OXIDE; OXIDATIVE STRESS; PHENYLALANINE; PHENYLKETONURIAS; VITAMIN D;

EID: 84897059113     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.09.007     Document Type: Review

References (59)

1. Scriver C.R., Kaufman S. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. The Metabolic and Molecular Bases of Inherited Disease 2001, 1667-1724. McGraw-Hill, New York. eighth ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Sly (Eds.).
2. Hanley W.B. Adult phenylketonuria. Am. J. Med. 2004, 117:590-595.
3. Lee P.J., Amos A., Robertson L., Fitzgerald B., Hoskin R., Lilburn M., Weetch E., Murphy G. Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted diet. J. Neurol. Neurosurg. Psychiatry 2009, 80:631-635.
4. Trefz F., Maillot F., Motzfeldt K., Schwarz M. Adult phenylketonuria outcome and management. Mol. Genet. Metab. 2011, 104:S26-S30. (Suppl.).
5. Hoedt A.E., de Sonneville L.M., Francois B.,Horst N.M., Janssen M.C., Rubio-Gozalbo M.E., Wijburg F.A., Hollak C.E., Bosch A.M. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J. Inherit. Metab. Dis. 2011, 34:165-171.
6. Blau N., van Spronsen F.J., Levy H. Phenylketonuria. Lancet 2010, 376:1417-1427.
7. Martynyuk A.E., van Spronsen F.J., Van der Zee E.A. Animal models of brain dysfunction in phenylketonuria. Mol. Genet. Metab. 2010, 99(Suppl. 1):S100-S105.
8. Wyse A.T., Noriler M.E., Borges L.F., Floriano P.J., Silva C.G., Wajner M., Wannmacher C.M. Alanine prevents the decrease of Na+, K+-ATPase activity in experimental phenylketonuria. Metab. Brain Dis. 1999, 14:95-101.
9. Sanayama Y., Nagasaka H., Takayanagi M., Ohura T., Sakamoto O., Ito T., Ishige-Wada M., Usui H., Yoshino M., Ohtake A., Yorifuji T., Tsukahara H., Hirayama S., Miida T., Fukui M., Okano Y. Experimental evidence that phenylalanine is strongly associated to oxidative stress in adolescents and adults with phenylketonuria. Mol. Genet. Metab. 2011, 103:220-225.
10. Nagasaka H., Okano Y., Kimura A., Mizuochi T.T., Sanayama Y., Takatani T., Nakagawa S., Hasegawa E., Hirano K., Mochizuki H., Ohura T., Ishige-Wada M., Usui H., Yorifuji T., Tsukahara H., Hirayama S., Ohtake A., Yamato S., Miida T. Oxysterol changes along with cholesterol and vitamin D changes in adult phenylketonuric patients diagnosed by newborn mass-screening. Clin. Chim. Acta 2013, 416:54-59.
11. Nagasaka H., Tsukahara H., Takatani T., Sanayama Y., Takayanagi M., Ohura T., Sakamoto O., Ito T., Wada M., Yoshino M., Ohtake A., Yorifuji T., Hirayama S., Miida T., Fujimoto H., Mochizuki H., Hattori T., Okano Y. Cross-sectional study of bone metabolism with nutrition in adult classical phenylketonuric patients diagnosed by neonatal screening. J. Bone Miner. Metab. 2011, 29:737-743.
12. Kono K., Okano Y., Nakayama K., Hase Y., Minamikawa S., Ozawa N., Yokote H., Inoue Y. Diffusion-weighted MR imaging in patients with phenylketonuria: relationship between serum phenylalanine levels and ADC values in cerebral white matter. Radiology 2005, 236:630-636.
13. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?. Lancet 1994, 344:721-724.
14. Reznick A.Z., Packer L. Free radicals and antioxidants in muscular neurological diseases and disorders. Free Radical: From Basic Science to Medicine 1993, 425-437. Birkhauser Verlag, Basel. G. Poli, B. Albano, M.U. Dianzani (Eds.).
15. Przedborski S., Donaldson D., Jacowec M., Kish S.J., Guttman M., Rosoklija G., Hays A.P. Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis. Ann. Neurol. 1996, 39:158-165.
16. Khan S., O'Brien P.J. Modulating hypoxia-induced hepatocyte injury by affecting intracellular redox state. Biochim. Biophys. Acta 1995, 1269:153-161.
17. Williamson J.R., Kilo C., Ido Y. The role of cytosolic reductive stress in oxidant formation and diabetic complications. Diabetes Res. Clin. Pract. 1999, 45:81-82.
18. Russell D.W. Oxysterol biosynthetic enzymes. Biochim. Biophys. Acta 2000, 1529:126-135.
19. Alkazemi D., Egeland G., Vaya J., Meltzer S., Kubow S. Oxysterol as a marker of atherogenic dyslipidemia in adolescence. J. Clin. Endocrinol. Metab. 2008, 93:4282-4289.
20. Sirtori L.R., Dutra-Filho C.S., Fitarelli D., Sitta A., Haeser A., Barschak A.G., Wajner M., Coelho D.M., Llesuy S., Belló-Klein A., Giugliani R., Deon M., Vargas C.R. Oxidative stress in patients with phenylketonuria. Biochim. Biophys. Acta 2005, 1740:68-73.
21. Artuch R., Colomé C., Sierra C., Brandi N., Lambruschini N., Campistol J., Ugarte D., Vilaseca M.A. A longitudinal study of antioxidant status in phenylketonuric patients. Clin. Biochem. 2004, 37:198-203.
22. Sierra C., Vilaseca M.A., Moyano D., Brandi N., Campistol J., Lambruschini N., Cambra F.J., Deulofen R., Mira A. Antioxidant status in hyperphenylalaninemia. Clin. Chim. Acta 1998, 276:1-9.
23. Mori M., Gotoh T. Arginine metabolic enzymes, nitric oxide and infection. J. Nutr. 2004, 134:2820S-2825S.
24. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991, 43:109-142.
25. Huemer M., Simma B., Mayr D., Möslinge D., Mühl A., Schumid I., Ulmer H., Bodamer O.A. Free asymmetric dimethylarginine (ADMA) is low in children and adolescents with classical phenylketonuria (PKU). J. Inherit. Metab. Dis. 2012, 35:817-821.
26. Förstermann U., Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006, 113:1708-1714.
27. Karaa A., Kamoun W.S., Clemens M.G. Oxidative stress disrupts nitric oxide synthase activation in liver endothelial cells. Free Radic. Biol. Med. 2005, 39:1320-1331.
28. Barat P., Barthe N., Redonnet-Vernhet I., Parrot F. The impact of the control of serum phenylalanine levels on osteopenia in patients with phenylketonuria. Eur. J. Pediatr. 2002, 161:687-688.
29. Millet P., Vilaseca M.A., Valls C., Pérez-Dueñas B., Artuch R., Gómez L., Lambruschini N., Campistol J. Is deoxypyridinoline a good resorption marker to detect osteopenia in phenylketonuria?. Clin. Biochem. 2005, 38:1127-1132.
30. Ambroszkiewicz J., Gajewska J., Laskowska-Klita T. A study of bone turnover markers in prepubertal children with phenylketonuria. Eur. J. Pediatr. 2004, 163:177-178.
31. AI-Qadreh A., Schulpis K.H., Athanasopoulou H., Mengreli C., Skarpalezou A., Voskaki I. Bone mineral status in children with phenylketonuria under treatment. Acta Pediatr. 1998, 87:1162-1166.
32. Modan-Moses D., Vered I., Schwartz G., Anikster Y., Abraham S., Segev R., Efrati O. Peak bone mass in patients with phenylketonuria. J. Inherit. Metab. Dis. 2007, 30:202-208.
33. Pagani F., Francucci C.M., Moro L. Markers of bone turnover: biochemical and clinical perspectives. J. Endocrinol. Invest. 2005, 28(Suppl. 10):8-13.
34. Szulc P., Seeman E., Delmas P.D. Biochemical measurements of bone turnover in children and adolescents. Osteoporos. Int. 2000, 11:281-294.
35. Hargreaves I.P. Coenzyme Q10 in phenylketonuria and mevalonicaciduria. Mitochondrion 2007, 7:S175-S180.
36. Castillo M., Zafra M.F., Garcia-Peregrin E. Inhibition of brain and liver 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase in experimental hyperphenylalaninemia. Neurochem. Res. 1988, 13:551-555.
37. Shefer S., Tint G.S., Jean-Guillaume D., Daikhin E., Kendler A., Nguyen L.B., Yudkoff M., Dyer C.A. Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse?. J. Neurosci. Res. 2000, 61:549-563.
38. Jeitner T.M., Voloshyna I., Reiss A.B. Oxysterol derivatives of cholesterol in neurodegenerative disorders. Curr. Med. Chem. 2011, 18:1515-1525.
39. Shafaati M., Marutle A., Pettersson H., Lövgren-Sandblom A., Olin M., Pikuleva I., Winblad B., Nordberg A., Björkhem I. Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation. J. Lipid Res. 2011, 52:1004-1010.
40. Leoni V., Caccia C. Oxysterols as biomarkers in neurodegenerative diseases. Chem. Phys. Lipids 2011, 164:515-524.
41. Schüle R., Siddique T., Deng H.X., Yang Y., Donkervoort S., Hansson M., Madrid R.E., Siddique N., Schöls L., Björkhem I. Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis. J. Lipid Res. 2010, 51:819-823.
42. Lund E.G., Guileyardo J.M., Russell D.W. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7238-7243.
43. Bryleva E.Y., Rogers M.A., Chang C.C., Buen F., Harris B.T., Rousselet E., Seidah N.G., Oddo S., LaFerla F.M., Spencer T.A., Hickey W.F., Chang T.Y. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3081-3086.
44. Kim W.S., Chan S.L., Hill A.F., Guillemin G.J., Garner B. Impact of 27-hydroxycholesterol on amyloid-beta peptide production and ATP-binding cassette transporter expression in primary human neurons. J. Alzheimers Dis. 2009, 16:121-131.
45. Ullrich C., Pirchl M., Humpel C. Effects of cholesterol and its 24S-OH and 25-OH oxysterols on choline acetyltransferase-positive neurons in brain slices. Pharmacology 2010, 86:15-21.
46. Lütjohann D. Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol. Scand. Suppl. 2006, 185:33-42.
47. Bick U., Fahrendorf G., Ludolph A.C., Vassallo P., Weglage J., Ullrich K. Disturbed myelination in patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging. Eur. J. Pediatr. 1991, 150:185-189.
48. Thompson A.J., Tillotson S., Smith I., Kendall B., Moore S.G., Brenton D.P. Brain MRI changes in phenylketonuria. Associations with dietary status. Brain 1993, 116:811-821.
49. Cleary M.A., Walter J.H., Wraith J.E., Jenkins J.P., Alani S.M., Tyler K., Whittle D. Magnetic resonance imaging of the brain in phenylketonuria. Lancet 1994, 344:87-90.
50. 1H MRS) study. J. Inherit. Metab. Dis. 2007, 30:209-216.
51. Scarabino T., Popolizio T., Tosetti M., Montanaro D., Giannatempo G.M., Terlizzi R., Pollice S., Maiorana A., Maggialetti N., Carriero A., Leuzzi V., Salvolini U. Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion. Radiol. Med. 2009, 114:461-474.
52. Bick U., Ullrich K., Stöber U., Möller H., Schuierer G., Ludolph A.C., Oberwittler C., Weglage J., Wendel U. White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings. Eur. J. Pediatr. 1993, 152:1012-1020.
53. Cleary M.A., Walter J.H., Wraith J.E., White F., Tyler K., Jenkins J.P.R. Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. J. Pediatr. 1995, 127:251-255.
54. Manara R., Burlina A.P., Citton V., Ermani M., Vespignani F., Carollo C., Burlina A.B. Brain MRI diffusion-weighted imaging in patients with classical phenylketonuria. Neuroradiology 2009, 51:803-812.
55. Thompson A.J., Smith I., Brenton D., Youl B.D., Rylance G., Davidson D.C., Kendall B., Lees A.J. Neurological deterioration in young adults with phenylketonuria. Lancet 1990, 336:602-605.
56. Antenor-Dorsey J.A., Hershey T., Rutlin J., Shimony J.S., McKinstry R.C., Grange D.K., Christ S.E., White D.A. White matter integrity and executive abilities in individuals with phenylketonuria. Mol. Genet. Metab. 2013, 109:125-131.
57. Lenke R.R., Levy H.L. Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies. N. Engl. J. Med. 1980, 303:1202-1208.
58. Okano Y., Chow I.Z., Isshiki G., Inoue A., Oura T. Effects of phenylalanine loading on protein synthesis in the fetal heart and brain of rat: an experimental approach to maternal phenylketonuria. J. Inherit. Metab. Dis. 1986, 9:15-24.
59. Aoki K., Siegel F.L. Hyperphenylalaninemia: disaggregation of brain polyribosomes in young rats. Science 1970, 168:129-130.